Last €87.72 EUR
Change Today +18.05 / 25.91%
Volume 220.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 12:51 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Open
€68.31
Previous Close
€69.67
Day High
€87.72
Day Low
€68.31
52 Week High
08/29/14 - €87.72
52 Week Low
09/2/13 - €53.47
Market Cap
4.1B
Average Volume 10 Days
32.0
EPS TTM
--
Shares Outstanding
47.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTH)

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $992.7K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $808.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $543.8K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

united therapeutics corp (UTH) Key Developments

United Therapeutics Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

United Therapeutics Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenues were $322,802,000 against $280,606,000 for the same period a year ago. Income before income taxes was $173,033,000 against $118,519,000 for the same period a year ago. Operating income was $176,320,000 against $122,304,000 for the same period a year ago. Net income was $111,852,000 against $79,864,000 for the same period a year ago. Net income per common share diluted was $2.10 against $1.52 for the same period a year ago. Non-GAAP earnings were $122,366,000 against $125,050,000 for the same period a year ago. Non-GAAP earnings per share diluted were $2.30 against $2.38 for the same period a year ago. For the six months, total revenues were $612,205,000 against $525,742,000 for the same period a year ago. Income before income taxes was $386,249,000 against $209,354,000 for the same period a year ago. Operating income was $392,460,000 against $216,341,000 for the same period a year ago. Net income was $249,376,000 against $142,189,000 for the same period a year ago. Net income per common share diluted was $4.54 against $2.71 for the same period a year ago.

United Therapeutics Corporation to Report Q2, 2014 Results on Jul 29, 2014

United Therapeutics Corporation announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 29, 2014

United Therapeutics Corporation, Q2 2014 Earnings Call, Jul 29, 2014

United Therapeutics Corporation, Q2 2014 Earnings Call, Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €87.72 EUR +18.05

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for UTH.
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
No financial data is available for UTH.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.